RS20120253A1 - TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS - Google Patents

TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS

Info

Publication number: RS20120253A1
Authority: RS; Serbia
Prior art keywords: taci; receptor; fusion proteins; immunoglobulin fusion; ligand
Prior art date: 2001-05-24

Application number

RS20120253A

Other languages

English (en)

Serbian (sr)

Inventor

Mark W. Rixon

Jane A. Gross

Original Assignee

Zymogenetics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2002-05-20

Publication date

2013-02-28

2002-05-20 Application filed by Zymogenetics Inc. filed Critical Zymogenetics Inc.

2013-02-28 Publication of RS20120253A1 publication Critical patent/RS20120253A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Neurology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)

RS20120253A 2001-05-24 2002-05-20 TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS RS20120253A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29334301P	2001-05-24	2001-05-24

Publications (1)

Publication Number	Publication Date
RS20120253A1 true RS20120253A1 (en)	2013-02-28

Family

ID=23128690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20120253A RS20120253A1 (en)	2001-05-24	2002-05-20	TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS
YU92503A RS52228B (en)	2001-05-24	2002-05-20	TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
YU92503A RS52228B (en)	2001-05-24	2002-05-20	TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS

Country Status (28)

Country	Link
US (9)	US20030103986A1 (ru)
EP (2)	EP2116259B1 (ru)
JP (2)	JP2004535182A (ru)
KR (3)	KR101021124B1 (ru)
CN (2)	CN101628111B (ru)
AT (2)	ATE446771T1 (ru)
AU (1)	AU2002305646C1 (ru)
BR (1)	BRPI0209933B8 (ru)
CA (1)	CA2448123C (ru)
CY (2)	CY1109751T1 (ru)
DE (1)	DE60234202D1 (ru)
DK (2)	DK1436003T3 (ru)
EA (2)	EA010594B1 (ru)
ES (2)	ES2334772T7 (ru)
HK (2)	HK1076603A1 (ru)
HR (2)	HRP20030948B1 (ru)
IL (2)	IL158920A0 (ru)
ME (1)	MEP21708A (ru)
MX (1)	MXPA03010687A (ru)
NO (1)	NO337295B1 (ru)
NZ (1)	NZ529638A (ru)
PL (2)	PL219013B1 (ru)
PT (2)	PT2116259E (ru)
RS (2)	RS20120253A1 (ru)
SI (2)	SI1436003T1 (ru)
UA (1)	UA82830C2 (ru)
WO (1)	WO2002094852A2 (ru)
ZA (1)	ZA200308984B (ru)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7833529B1 (en) *	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US6969519B2 (en)	2000-03-10	2005-11-29	Human Genome Sciences, Inc.	Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
EP1294769B1 (en) *	2000-06-16	2011-01-05	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
EP2267018A3 (en)	2000-08-18	2011-04-20	Human Genome Sciences, Inc.	Binding polypeptides for B lymphocyte stimulator protein (BLyS)
CA2446734A1 (en)	2001-05-24	2002-11-28	Human Genome Sciences, Inc.	Antibodies against tumor necrosis factor delta (april)
EA010594B1 (ru) *	2001-05-24	2008-10-30	Займодженетикс, Инк.	Слитые белки taci-иммуноглобулина
CA2453995A1 (en) *	2001-08-03	2003-02-20	Genentech, Inc.	Tacis and br3 polypeptides and uses thereof
US7112410B1 (en)	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
AU2002330074A1 (en) *	2001-09-21	2003-04-01	Amgen Inc.	Tall-1 receptor molecules and uses thereof
AU2003222664A1 (en) *	2002-04-18	2003-11-03	Genencor International, Inc.	Production of functional antibodies in filamentous fungi
AU2003267967B2 (en) *	2002-06-18	2008-11-20	Zymogenetics, Inc.	Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
CA2501459A1 (en) *	2002-10-11	2004-04-22	Zymogenetics, Inc.	Production of homotrimeric fusion proteins
EP2478912B1 (en)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
ATE517914T1 (de)	2004-03-08	2011-08-15	Zymogenetics Inc	Dimere fusionsproteine und materialien und verfahren zu deren herstellung
RU2404810C9 (ru)	2004-06-01	2015-06-20	Дженентек, Инк.	Конъюгаты антитело-лекарственное средство и способы
AU2005266875B2 (en)	2004-07-23	2012-07-26	Acceleron Pharma Inc.	ActRII receptor polypeptides, methods and compositions
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh)	2004-09-23	2014-12-10	健泰科生物技术公司	半胱氨酸改造的抗体和偶联物
ES2336832T3 (es)	2005-07-22	2010-04-16	Five Prime Therapeutics, Inc.	Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
CA2618763A1 (en) *	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (en)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Methods for treating b-cell malignancies using taci-ig fusion molecule
WO2007019618A1 (en) *	2005-08-12	2007-02-22	Garvan Institute Of Medical Research	Phrophylactic and/or therapeutic method for treatment of autoimmune disease
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
SG10201509620SA (en)	2005-11-23	2015-12-30	Acceleron Pharma Inc	Activin-actriia antagonists and uses for promoting bone growth
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007117762A1 (en) *	2006-02-10	2007-10-18	Zymogenetics, Inc.	Truncated il-17ra soluble receptor and methods of using in inflammation
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
WO2007134326A2 (en) *	2006-05-15	2007-11-22	Ares Trading S.A.	Methods for treating autoimmune diseases using a taci-ig fusion molecule
CA2661936A1 (en) *	2006-08-25	2008-02-28	Margaret D. Moore	Soluble il-27 receptor
MX2009002013A (es) *	2006-08-28	2009-03-09	Ares Trading Sa	Proceso para la purificacion de proteinas de fusion fc.
ZA200900837B (en) *	2006-08-28	2010-05-26	Ares Trading Sa	Process for the purification of FC-containing proteins
JP2010501622A (ja) *	2006-08-28	2010-01-21	アレストレーディングソシエテアノニム	Ｆｃ−融合タンパク質の精製法
US8513393B2 (en)	2006-08-28	2013-08-20	Ares Trading S.A.	Process for the purification of Fc-containing proteins
EP2752423A3 (en) *	2006-09-18	2015-02-18	Compugen Ltd.	GPCR ligands and method of using same
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100063257A1 (en) *	2007-01-26	2010-03-11	Merck Serono Sa	Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
TW201716081A (zh)	2007-02-01	2017-05-16	艾瑟勒朗法瑪公司	活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201940502A (zh)	2007-02-02	2019-10-16	美商艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX368173B (es)	2007-02-09	2019-09-23	Acceleron Pharma Inc	Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
PL2139517T3 (pl)	2007-03-27	2013-10-31	Zymogenetics Inc	Kombinacja hamowania BLyS i mykofenolanu mofetylu do leczenia choroby autoimmunologicznej
WO2008116262A1 (en) *	2007-03-27	2008-10-02	Christopher Hovens	Methods and compositions for treating prostate cancer
CN101323643B (zh) *	2007-06-15	2010-12-01	烟台荣昌生物工程有限公司	优化的TACI-Fc融合蛋白
HUE042982T2 (hu)	2007-09-04	2019-07-29	Compugen Ltd	Polipeptidek és polinukleotidok, és alkalmazásuk drogcélpontként drogok és biológiai szerek elõállítására
JP2010539236A (ja)	2007-09-18	2010-12-16	アクセルロンファーマ，インコーポレイテッド	アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
HUE030134T2 (en) *	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US20100239580A1 (en) *	2007-11-12	2010-09-23	Area Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of optic neuritis
US20100261887A1 (en) *	2007-11-12	2010-10-14	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
AU2008322930B2 (en)	2007-11-12	2014-05-15	Ares Trading S.A.	Formulations for TACI-immunoglobulin fusion proteins
WO2010055366A2 (en)	2007-12-07	2010-05-20	Zymogenetics, Inc.	Anti-human il-21 monoclonal antibodies
EP2240196A2 (en) *	2008-01-22	2010-10-20	Compugen Ltd.	Clusterin derived peptide
AU2009239437B2 (en)	2008-04-25	2014-11-13	University Of Washington	Levels of BCMA protein expression on B cells and use in diagnostic methods
US8003335B2 (en)	2008-04-30	2011-08-23	Universite Paris-SUD11	Levels of APRIL in serum and use in diagnostic methods
EP2291657B1 (en) *	2008-05-01	2016-04-13	Zymogenetics, Inc.	Levels of blys/april heterotrimers in serum and use in diagnostic methods
JP2011526154A (ja)	2008-06-27	2011-10-06	ザイモジェネティクス，インコーポレイテッド	可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu)	2008-08-14	2021-03-01	Acceleron Pharma Inc	GDF-csapdák
EP2343080B1 (en) *	2008-09-30	2017-11-08	Kyowa Hakko Kirin Co., Ltd.	PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN
EP2865689A1 (en)	2008-12-08	2015-04-29	Compugen Ltd.	FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9238878B2 (en) *	2009-02-17	2016-01-19	Redwood Bioscience, Inc.	Aldehyde-tagged protein-based drug carriers and methods of use
BRPI1014858A2 (pt) *	2009-03-30	2017-03-28	Acceleron Pharma Inc	"antagonistas de bmp-alk3 e usos para promover o crescimento ósseo"
BRPI1010587A2 (pt)	2009-06-08	2019-04-09	Acceleron Pharma Inc.	métodos para aumentar adipócitos termogênicos
KR20210136174A (ko)	2009-06-12	2021-11-16	악셀레론 파마 인코포레이티드	절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
WO2011031870A1 (en)	2009-09-09	2011-03-17	Centrose, Llc	Extracellular targeted drug conjugates
PT2498799T (pt)	2009-11-13	2016-11-04	Five Prime Therapeutics Inc	Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
CA2781152A1 (en)	2009-11-17	2011-05-26	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9428586B2 (en)	2009-12-01	2016-08-30	Compugen Ltd	Heparanase splice variant
WO2011102845A1 (en) *	2010-02-18	2011-08-25	Transtech Pharma, Inc.	Rage fusion protein compositions and methods of use
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
NZ602634A (en)	2010-03-26	2015-06-26	Dartmouth College	Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
PH12012501836A1 (en)	2010-04-15	2013-02-04	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
CN101851278B (zh) *	2010-05-26	2013-03-13	石药集团中奇制药技术（石家庄）有限公司	B细胞激活因子拮抗剂及其制备方法与用途
SG185428A1 (en)	2010-06-08	2012-12-28	Genentech Inc	Cysteine engineered antibodies and conjugates
CA2802017A1 (en)	2010-06-09	2011-12-15	Zymogenetics, Inc.	Dimeric vstm3 fusion proteins and related compositions and methods
CA2803391C (en)	2010-06-22	2021-11-09	Neogenix Oncology, Inc.	Npc1 antibodies that bind a muc5ac epitope
AU2011272941B2 (en)	2010-06-30	2014-05-29	Compugen Ltd.	C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
ES2719624T3 (es)	2010-09-23	2019-07-11	Prec Biologics Inc	Peptidomiméticos de cáncer de colon y de páncreas
US20120258496A1 (en) *	2010-09-27	2012-10-11	Boehringer Ingelheim International Gmbh	Production of low fucose antibodies in h4-ii-e rat cells
EP2638065A4 (en)	2010-11-08	2014-04-09	Acceleron Pharma Inc	ACTRIIA BINDING AGENTS AND USES THEREOF
US8481038B2 (en)	2010-11-15	2013-07-09	Five Prime Therapeutics, Inc.	Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN103313990B (zh)	2010-11-17	2016-07-20	基因泰克公司	丙氨酰美登醇抗体偶联物
US8992908B2 (en)	2010-11-23	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of oral mucositis
US8951972B2 (en)	2010-12-09	2015-02-10	Five Prime Therapeutics, Inc.	FGFR1 extracellular domain combination therapies for lung cancer
WO2012090150A2 (en)	2010-12-27	2012-07-05	Compugen Ltd	New cell-penetrating peptides and uses thereof
BR112013017980A2 (pt)	2011-01-14	2017-06-27	Redwood Bioscience Inc	polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
CN102085367B (zh) *	2011-01-19	2012-08-22	烟台荣昌生物工程有限公司	优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
EP2697256A1 (en)	2011-04-15	2014-02-19	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
ES2567276T3 (es)	2011-05-12	2016-04-21	Genentech, Inc.	Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
ES2765874T3 (es)	2011-05-25	2020-06-11	Innate Pharma Sa	Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
CA2850371C (en)	2011-10-14	2020-06-30	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
CN107823630A (zh)	2011-11-14	2018-03-23	戊瑞治疗有限公司	治疗癌症的方法
CA2848985A1 (en)	2012-02-01	2013-08-08	Compugen Ltd.	C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP6285923B2 (ja)	2012-06-22	2018-02-28	トラスティーズ・オブ・ダートマス・カレッジ	新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
CN109793893B (zh)	2012-09-07	2023-05-26	达特茅斯大学理事会	用于诊断和治疗癌症的vista调节剂
KR101986404B1 (ko)	2012-10-12	2019-06-07	에이디씨 테라퓨틱스 에스에이	피롤로벤조디아제핀-항체 컨주게이트
ME03486B (me)	2012-10-12	2020-01-20	Medimmune Ltd	Pirolobenzodiazepini i njihovi konjugati
LT2906298T (lt)	2012-10-12	2018-12-27	Adc Therapeutics Sa	Pirolbenzodiazepino-antikūno konjugatai
WO2014057120A1 (en)	2012-10-12	2014-04-17	Adc Therapeutics Sàrl	Pyrrolobenzodiazepine-antibody conjugates
PT2906296T (pt)	2012-10-12	2018-06-01	Medimmune Ltd	Conjugados de pirrolobenzodiazepina-anticorpo
LT2906251T (lt)	2012-10-12	2017-12-11	Adc Therapeutics Sa	Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
ES2680153T3 (es)	2012-10-12	2018-09-04	Adc Therapeutics Sa	Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
CN104936605A (zh)	2012-11-02	2015-09-23	细胞基因公司	激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
CN103833856B (zh) *	2012-11-22	2017-05-03	上海康岱生物医药技术股份有限公司	抑制taci‑baff复合物形成的融合蛋白及其制法和用途
CN110452242A (zh)	2012-12-21	2019-11-15	麦迪穆有限责任公司	吡咯并苯并二氮杂卓及其结合物
CA2894959C (en)	2012-12-21	2022-01-11	Spirogen Sarl	Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2014140862A2 (en)	2013-03-13	2014-09-18	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
EA027910B1 (ru)	2013-03-13	2017-09-29	Медимьюн Лимитед	Пирролобензодиазепины и их конъюгаты
ES2687439T3 (es)	2013-03-13	2018-10-25	Medimmune Limited	Pirrolobenzodiazepinas y conjugados de las mismas
BR112016002829A2 (pt)	2013-08-12	2017-09-19	Genentech Inc	Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
EP3054986B1 (en)	2013-10-11	2019-03-20	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en)	2013-10-11	2018-07-03	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)	2013-10-11	2013-11-27	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en)	2013-10-11	2015-04-16	Spirogen Sàrl	Pyrrolobenzodiazepine-antibody conjugates
MX2016007826A (es)	2013-12-16	2017-03-31	Genentech Inc	Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
MX2016007578A (es)	2013-12-16	2016-10-03	Genentech Inc	Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX371092B (es)	2013-12-16	2020-01-16	Genentech Inc	Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
LT3712174T (lt)	2013-12-24	2022-05-25	Janssen Pharmaceutica Nv	Anti vista antikūnai ir fragmentai
AU2015274504B2 (en)	2014-06-11	2021-02-04	Kathy A. Green	Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
BR122023023170A2 (pt)	2014-06-13	2024-02-20	Acceleron Pharma Inc.	Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
US20170275344A1 (en)	2014-08-26	2017-09-28	Compugen Ltd.	Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
US10188746B2 (en)	2014-09-10	2019-01-29	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
CA2957354A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Cysteine engineered antibodies and conjugates
EP3191134B1 (en)	2014-09-12	2019-11-20	Genentech, Inc.	Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017533887A (ja)	2014-09-17	2017-11-16	ジェネンテック，インコーポレイテッド	ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CA2965862A1 (en)	2014-10-28	2016-05-06	Merck Patent Gmbh	Methods for non-covalent fc-domain-containing protein display on the surface of cells and methods of screening thereof
JP6734271B2 (ja)	2014-11-03	2020-08-05	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用
BR112017011111A2 (pt)	2014-11-25	2017-12-26	Adc Therapeutics Sa	conjugados de pirrolobenzodiazepina-anticorpo
EP3226909A1 (en)	2014-12-03	2017-10-11	Genentech, Inc.	Quaternary amine compounds and antibody-drug conjugates thereof
ES2946160T3 (es)	2014-12-03	2023-07-13	Celgene Corp	Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
AU2015357463B2 (en)	2014-12-05	2021-10-07	Immunext, Inc.	Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
EP3722314A1 (en)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista antibodies and fragments
US11130818B2 (en)	2015-08-07	2021-09-28	Merck Patent Gmbh	Transglutamine tag for efficient site-specific bioconjugation
WO2017044424A1 (en)	2015-09-08	2017-03-16	Theripion, Inc.	Apoa-1 fusion polypeptides and related compositions and methods
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
US10899836B2 (en)	2016-02-12	2021-01-26	Janssen Pharmaceutica Nv	Method of identifying anti-VISTA antibodies
US20170315132A1 (en)	2016-03-25	2017-11-02	Genentech, Inc.	Multiplexed total antibody and antibody-conjugated drug quantification assay
JP7116685B2 (ja)	2016-04-15	2022-08-10	エイチ．ルンドベックアー／エス	ヒト化抗ｐａｃａｐ抗体及びそれらの使用
US20210017281A1 (en)	2016-04-15	2021-01-21	Immunext, Inc.	Anti-human vista antibodies and use thereof
US11208632B2 (en)	2016-04-26	2021-12-28	R.P. Scherer Technologies, Llc	Antibody conjugates and methods of making and using the same
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es)	2016-05-20	2021-09-29	Hoffmann La Roche	Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (en)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en)	2016-06-06	2021-10-06	F. Hoffmann-La Roche AG	Silvestrol antibody-drug conjugates and methods of use
US11649285B2 (en)	2016-08-03	2023-05-16	Bio-Techne Corporation	Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
CN109689111B (zh)	2016-08-11	2024-04-05	基因泰克公司	吡咯并苯并二氮杂䓬前药及其抗体缀合物
WO2018065501A1 (en)	2016-10-05	2018-04-12	F. Hoffmann-La Roche Ag	Methods for preparing antibody drug conjugates
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
WO2018136163A2 (en)	2016-12-09	2018-07-26	Theripion, Inc.	Tandem apoa-1 fusion polypeptides
KR102181375B1 (ko)	2017-02-08	2020-11-25	에이디씨 테라퓨틱스 에스에이	피롤로벤조디아제핀-항체 컨주게이트
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
HRP20221063T1 (hr)	2017-04-18	2022-11-11	Medimmune Limited	Konjugati pirolobenzodiazepina
JP7408396B2 (ja)	2017-04-20	2024-01-05	アーデーセーセラピューティクスソシエテアノニム	併用療法
JP7265788B2 (ja)	2017-05-09	2023-04-27	シアノバイオテックゲーエムベーハー	修飾ミクロシスチンおよびノジュラリン
EP3529364B1 (en)	2017-05-09	2020-01-01	Cyano Biotech GmbH	Method of producing a non-ribosomal peptide from cyanobacteria
UA127900C2 (uk)	2017-06-14	2024-02-07	Ейдісі Терапьютікс Са	Схема дозування для введення adc до cd19
SG11202000358YA (en)	2017-08-18	2020-02-27	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
EP3675897A1 (en)	2017-09-01	2020-07-08	Dana Farber Cancer Institute, Inc.	Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
TW201920192A (zh)	2017-09-20	2019-06-01	韓商Ｐｈ製藥公司	泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
WO2019152810A1 (en)	2018-02-02	2019-08-08	Bio-Techne Corporation	Compounds that modulate the interaction of vista and vsig3 and methods of making and using
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
IL282441B1 (en)	2018-10-24	2025-03-01	Hoffmann La Roche	Combined chemical influencing factors of decomposition and methods of use
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
CA3130174A1 (en)	2019-03-15	2020-09-24	Medimmune Limited	Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
US20220306734A1 (en)	2019-07-24	2022-09-29	H. Lundbeck A/S	Anti-mglur5 antibodies and uses thereof
EP3868403A4 (en) *	2019-12-24	2022-04-06	RemeGen Co., Ltd.	TACI-FC FUSION PROTEIN AND USE THEREOF
MX2022013999A (es)	2020-05-08	2023-02-16	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas.
EP4157316A4 (en) *	2020-06-02	2024-07-10	Ares Trading S.A.	PROCEDURES RELATED TO THE TREATMENT OF IGA NEPHROPATHY
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
EP4294916A2 (en)	2021-02-19	2023-12-27	Theripion, Inc.	Dnase fusion polypeptides and related compositions and methods
US20240279310A1 (en)	2021-05-07	2024-08-22	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
US20240270842A1 (en)	2021-05-07	2024-08-15	Viela Bio, Inc	Use of an anti-cd19 antibody to treat myasthenia gravis
JP2024512935A (ja) *	2021-09-30	2024-03-21	レメゲンシーオー．，エルティーディー．	ＴＡＣＩ－Ｆｃ融合タンパク質を用いたシェーグレン症候群の治療方法
TW202323304A (zh) *	2021-09-30	2023-06-16	大陸商江蘇恆瑞醫藥股份有限公司	抗ｉｌ２３抗體融合蛋白及用途
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联
WO2023236967A1 (zh) *	2022-06-08	2023-12-14	荣昌生物制药(烟台)股份有限公司	用TACI-Fc融合蛋白治疗重症肌无力的方法
CN119698304A (zh) *	2022-09-30	2025-03-25	荣昌生物制药(烟台)股份有限公司	用TACI-Fc融合蛋白治疗膜性肾病的方法
AU2023356958A1 (en)	2022-10-04	2025-04-03	Alpine Immune Sciences, Inc.	Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024114777A1 (zh) *	2022-12-02	2024-06-06	荣昌生物制药(烟台)股份有限公司	用TACI-Fc融合蛋白治疗微小病变型肾病的方法
WO2024123675A2 (en) *	2022-12-05	2024-06-13	Alexion Pharmaceuticals, Inc.	Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor
WO2024138128A2 (en)	2022-12-23	2024-06-27	Genentech, Inc.	Cereblon degrader conjugates, and uses thereof
US12173081B2 (en)	2023-03-21	2024-12-24	Biograph 55, Inc.	CD19/CD38 multispecific antibodies
WO2024220546A2 (en)	2023-04-17	2024-10-24	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024259220A1 (en)	2023-06-15	2024-12-19	Theripion, Inc.	Pon3 and evolved pon1 fusion polypeptides
WO2025007943A1 (zh) *	2023-07-06	2025-01-09	荣昌生物制药(烟台)股份有限公司	用taci-fc融合蛋白治疗anca相关性血管炎的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5738A (en)		1848-08-29		Francis kelsey
US846A (en)		1838-07-17		Improvement in revolving fire-arms
DK368882A (da)	1981-08-25	1983-02-26	Alan John Kingsman	Expessions vektorer
US4769331A (en)	1981-09-16	1988-09-06	University Patents, Inc.	Recombinant methods and materials
US4486533A (en)	1982-09-02	1984-12-04	St. Louis University	Filamentous fungi functional replicating extrachromosomal element
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en)	1985-06-26	1990-12-11	Amgen	Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US4661454A (en)	1983-02-28	1987-04-28	Collaborative Research, Inc.	GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en)	1983-02-28	1992-08-18	Collaborative Research, Inc.	Use of the GAL1 yeast promoter
US4870008A (en)	1983-08-12	1989-09-26	Chiron Corporation	Secretory expression in eukaryotes
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
US4931373A (en)	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US4859587A (en)	1984-06-04	1989-08-22	Institut Merieux	Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en)	1984-06-04	1994-02-22	Arch Development Corporation	Herpes Simplex virus as a vector
US4766073A (en)	1985-02-25	1988-08-23	Zymogenetics Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en)	1984-12-06	1991-02-05	Labofina, S.A.	Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
US4751181A (en)	1984-12-31	1988-06-14	Duke University	Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4882279A (en)	1985-10-25	1989-11-21	Phillips Petroleum Company	Site selective genomic modification of yeast of the genus pichia
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
US5063154A (en)	1987-06-24	1991-11-05	Whitehead Institute For Biomedical Research	Pheromone - inducible yeast promoter
US5037743A (en)	1988-08-05	1991-08-06	Zymogenetics, Inc.	BAR1 secretion signal
US5162228A (en)	1988-12-28	1992-11-10	Takeda Chemical Industries, Ltd.	Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5328688A (en)	1990-09-10	1994-07-12	Arch Development Corporation	Recombinant herpes simplex viruses vaccines and methods
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
JP3202999B2 (ja)	1991-01-31	2001-08-27	協和醗酵工業株式会社	肝移行性リポソーム製剤
US5298418A (en)	1991-09-16	1994-03-29	Boyce Thompson Institute For Plant Research, Inc.	Cell line isolated from larval midgut tissue of Trichoplusia ni
US5861151A (en) *	1991-12-20	1999-01-19	Bristol-Myers Squibb Co	Soluble fusion molecules with binding specificity for cell adhesion molecules
ZA932522B (en) *	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ZA932523B (en) *	1992-04-10	1994-10-08	Res Dev Foundation	Immunotoxins directed against cd33 related surface antigens
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
WO1994009137A1 (en)	1992-10-15	1994-04-28	Genentech, Inc.	Antibodies against type 2 tumor necrosis factor receptor
US5650550A (en)	1993-10-01	1997-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Mutant mice having a deficit of functional estrogen receptors
US5523227A (en)	1994-06-17	1996-06-04	The Board Of Trustees Of The Leland Stanford Junior Univ.	DNA encoding calcium-signal modulating cyclophilin ligand
MX9704501A (es)	1994-12-15	1997-10-31	Yeda Res & Dev	Moduladores de la funcion de receptores de fas/ap01.
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
DE19533447C1 (de)	1995-09-09	1996-12-05	Bbs Kraftfahrzeugtechnik	Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
JP2000500014A (ja)	1995-11-09	2000-01-11	ザイモジェネティクス，インコーポレイティド	ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
US5716808A (en)	1995-11-09	1998-02-10	Zymogenetics, Inc.	Genetic engineering of pichia methanolica
PT897390E (pt)	1996-03-14	2004-03-31	Human Genome Sciences Inc	Factor delta e epsilon de necrose tumoral humana
AU718510B2 (en)	1996-07-17	2000-04-13	Zymogenetics Inc.	Transformation of pichia methanolica
US5736383A (en)	1996-08-26	1998-04-07	Zymogenetics, Inc.	Preparation of Pichia methanolica auxotrophic mutants
IL128072A0 (en)	1996-07-17	1999-11-30	Zymogenetics Inc	Preparation of pichia methanolica auxotrophic mutants
ES2248823T5 (es)	1996-10-25	2011-11-03	Human Genome Sciences, Inc.	Neutroquina alfa.
AU5705898A (en)	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
JP2001515360A (ja) *	1997-04-18	2001-09-18	バイオジェン，インコーポレイテッド	▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
IL133316A0 (en)	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
WO1998055620A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
AU9013998A (en) *	1997-07-21	1999-02-10	Zymogenetics Inc.	Tumor necrosis factor receptor ztnfr-5
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
SK3542000A3 (en)	1997-09-12	2000-08-14	Apotech R & D Sa	Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
US20060067933A1 (en) *	1999-01-07	2006-03-30	Gross Jane A	Soluble receptor BR43x2 and methods of using
NZ512753A (en) *	1999-01-07	2003-10-31	Zymogenetics Inc	Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4
TR200102147T2 (tr)	1999-01-25	2002-04-22	Biogen, Inc.	BAFF, ilişkili bloke edici maddeler ve bunların bağışıklık karşılığında B-hücreleri ve imünoglobülinlerin uyarımı ve engellenmesinde kullanımları
WO2000062790A2 (en)	1999-04-19	2000-10-26	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001012812A2 (en)	1999-08-17	2001-02-22	Biogen, Inc.	Baff receptor (bcma), an immunoregulatory agent
EP1218411A4 (en) *	1999-09-20	2004-09-01	Millennium Pharm Inc	SECRETED PROTEINS AND THEIR USES
UA74798C2 (ru)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Способ лечения рака у млекопитающих с помощью полипептида, который препятствует взаимодействию между april и его рецепторами
AU2048501A (en)	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
PT2857516T (pt)	2000-04-11	2017-08-28	Genentech Inc	Anticorpos multivalentes e utilizações dos mesmos
AU5392001A (en) *	2000-04-27	2001-11-07	Biogen Inc	Taci as an anti-tumor agent
ATE361318T1 (de) *	2000-05-12	2007-05-15	Amgen Inc	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
ES2344679T3 (es)	2000-08-11	2010-09-03	Kyowa Hakko Kirin Co., Ltd.	Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican.
AU2002230659A1 (en)	2000-11-07	2002-05-21	Zymogenetics Inc.	Human tumor necrosis factor receptor
CA2438682A1 (en) *	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
EA010594B1 (ru) *	2001-05-24	2008-10-30	Займодженетикс, Инк.	Слитые белки taci-иммуноглобулина
AU2008322930B2 (en)	2007-11-12	2014-05-15	Ares Trading S.A.	Formulations for TACI-immunoglobulin fusion proteins

2002
- 2002-05-20 EA EA200600894A patent/EA010594B1/ru not_active IP Right Cessation
- 2002-05-20 ME MEP-217/08A patent/MEP21708A/xx unknown
- 2002-05-20 US US10/152,363 patent/US20030103986A1/en not_active Abandoned
- 2002-05-20 ES ES02734478T patent/ES2334772T7/es active Active
- 2002-05-20 UA UA20031110605A patent/UA82830C2/uk unknown
- 2002-05-20 MX MXPA03010687A patent/MXPA03010687A/es active IP Right Grant
- 2002-05-20 JP JP2002592326A patent/JP2004535182A/ja not_active Withdrawn
- 2002-05-20 RS RS20120253A patent/RS20120253A1/en unknown
- 2002-05-20 ES ES09168970T patent/ES2379977T3/es not_active Expired - Lifetime
- 2002-05-20 PL PL366760A patent/PL219013B1/pl not_active IP Right Cessation
- 2002-05-20 DK DK02734478.7T patent/DK1436003T3/da active
- 2002-05-20 DK DK09168970.3T patent/DK2116259T3/da active
- 2002-05-20 PT PT09168970T patent/PT2116259E/pt unknown
- 2002-05-20 BR BR0209933-0 patent/BRPI0209933B8/pt not_active IP Right Cessation
- 2002-05-20 KR KR1020107010485A patent/KR101021124B1/ko not_active Expired - Lifetime
- 2002-05-20 AT AT02734478T patent/ATE446771T1/de active
- 2002-05-20 NZ NZ529638A patent/NZ529638A/en not_active IP Right Cessation
- 2002-05-20 DE DE60234202T patent/DE60234202D1/de not_active Expired - Lifetime
- 2002-05-20 CN CN200910146212XA patent/CN101628111B/zh not_active Expired - Lifetime
- 2002-05-20 PL PL403488A patent/PL403488A1/pl not_active Application Discontinuation
- 2002-05-20 EA EA200301146A patent/EA007275B1/ru not_active IP Right Cessation
- 2002-05-20 EP EP09168970A patent/EP2116259B1/en not_active Expired - Lifetime
- 2002-05-20 CA CA2448123A patent/CA2448123C/en not_active Expired - Lifetime
- 2002-05-20 IL IL15892002A patent/IL158920A0/xx active IP Right Grant
- 2002-05-20 RS YU92503A patent/RS52228B/en unknown
- 2002-05-20 PT PT02734478T patent/PT1436003E/pt unknown
- 2002-05-20 KR KR10-2003-7015353A patent/KR20040030628A/ko not_active Application Discontinuation
- 2002-05-20 WO PCT/US2002/015910 patent/WO2002094852A2/en active Application Filing
- 2002-05-20 KR KR1020097013141A patent/KR100976743B1/ko not_active Expired - Lifetime
- 2002-05-20 AU AU2002305646A patent/AU2002305646C1/en not_active Expired
- 2002-05-20 SI SI200230868T patent/SI1436003T1/sl unknown
- 2002-05-20 CN CN02812698XA patent/CN1612750B/zh not_active Expired - Lifetime
- 2002-05-20 EP EP02734478A patent/EP1436003B3/en not_active Expired - Lifetime
- 2002-05-20 AT AT09168970T patent/ATE542545T1/de active
- 2002-05-20 SI SI200230979T patent/SI2116259T1/sl unknown
2003
- 2003-11-19 ZA ZA200308984A patent/ZA200308984B/en unknown
- 2003-11-20 HR HRP20030948AA patent/HRP20030948B1/hr not_active IP Right Cessation
- 2003-11-21 NO NO20035173A patent/NO337295B1/no not_active IP Right Cessation
2005
- 2005-09-29 HK HK05108608.2A patent/HK1076603A1/xx not_active IP Right Cessation
- 2005-10-03 US US11/242,294 patent/US7501497B2/en not_active Expired - Lifetime
2009
- 2009-01-26 US US12/359,801 patent/US7635767B2/en not_active Expired - Lifetime
- 2009-06-22 JP JP2009147774A patent/JP5149245B2/ja not_active Expired - Lifetime
- 2009-10-26 US US12/605,561 patent/US7964711B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,288 patent/US7951919B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/613,039 patent/US7862814B2/en not_active Expired - Fee Related
2010
- 2010-01-27 CY CY20101100079T patent/CY1109751T1/el unknown
- 2010-03-19 HK HK10102899.6A patent/HK1137659A1/xx not_active IP Right Cessation
2011
- 2011-05-11 US US13/105,182 patent/US8524232B2/en not_active Expired - Lifetime
- 2011-12-29 IL IL217265A patent/IL217265A/en active IP Right Grant
2012
- 2012-04-24 CY CY20121100381T patent/CY1112840T1/el unknown
2013
- 2013-05-09 HR HRP20130413AA patent/HRP20130413A2/hr not_active Application Discontinuation
- 2013-08-01 US US13/956,499 patent/US8815238B2/en not_active Expired - Lifetime
2014
- 2014-07-15 US US14/331,567 patent/US9346878B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE542545T1 (de)	2012-02-15
ES2334772T7 (es)	2012-11-19
US20090209006A1 (en)	2009-08-20
KR100976743B1 (ko)	2010-08-19
EP2116259A1 (en)	2009-11-11
CN101628111B (zh)	2013-11-06
NZ529638A (en)	2007-08-31
EA010594B1 (ru)	2008-10-30
YU92503A (sh)	2006-05-25
CN1612750B (zh)	2012-10-31
PT1436003E (pt)	2010-03-12
US7862814B2 (en)	2011-01-04
IL217265A (en)	2013-05-30
MXPA03010687A (es)	2004-07-01
US7635767B2 (en)	2009-12-22
JP5149245B2 (ja)	2013-02-20
AU2002305646C1 (en)	2009-08-06
DK1436003T3 (da)	2010-03-15
HRP20030948B1 (hr)	2013-06-30
US20030103986A1 (en)	2003-06-05
US7501497B2 (en)	2009-03-10
BRPI0209933B8 (pt)	2021-05-25
US20110229473A1 (en)	2011-09-22
EP1436003A4 (en)	2005-04-27
CN101628111A (zh)	2010-01-20
HK1076603A1 (en)	2006-01-20
WO2002094852A2 (en)	2002-11-28
EP1436003B3 (en)	2012-03-14
US8815238B2 (en)	2014-08-26
US8524232B2 (en)	2013-09-03
US20100183609A1 (en)	2010-07-22
AU2002305646B2 (en)	2008-09-04
US9346878B2 (en)	2016-05-24
SI1436003T1 (sl)	2010-02-26
JP2004535182A (ja)	2004-11-25
EA007275B1 (ru)	2006-08-25
CA2448123C (en)	2012-09-11
NO337295B1 (no)	2016-03-07
CN1612750A (zh)	2005-05-04
DK2116259T3 (da)	2012-05-21
UA82830C2 (en)	2008-05-26
US20140328844A1 (en)	2014-11-06
SI2116259T1 (sl)	2012-11-30
PL219013B1 (pl)	2015-02-27
US20100129384A1 (en)	2010-05-27
PT2116259E (pt)	2012-04-09
CY1109751T1 (el)	2014-09-10
DE60234202D1 (de)	2009-12-10
PL366760A1 (en)	2005-02-07
IL158920A0 (en)	2004-05-12
HRP20130413A2 (hr)	2013-07-31
BRPI0209933B1 (pt)	2018-10-16
US20130309231A1 (en)	2013-11-21
ZA200308984B (en)	2004-07-20
KR20040030628A (ko)	2004-04-09
ES2334772T3 (es)	2010-03-16
ATE446771T1 (de)	2009-11-15
PL403488A1 (pl)	2013-07-08
MEP21708A (en)	2010-06-10
EP1436003A2 (en)	2004-07-14
WO2002094852A8 (en)	2004-04-22
EP1436003B1 (en)	2009-10-28
KR20090080570A (ko)	2009-07-24
KR20100061860A (ko)	2010-06-09
RS52228B (en)	2012-10-31
IL217265A0 (en)	2012-02-29
BR0209933A (pt)	2004-03-30
HRP20030948A2 (en)	2004-06-30
CY1112840T1 (el)	2016-02-10
ES2379977T3 (es)	2012-05-07
US7964711B2 (en)	2011-06-21
US20100130728A1 (en)	2010-05-27
EA200301146A3 (ru)	2005-02-24
EA200301146A2 (ru)	2004-06-24
NO20035173D0 (no)	2003-11-21
HK1137659A1 (en)	2010-08-06
EP2116259B1 (en)	2012-01-25
US7951919B2 (en)	2011-05-31
EA200600894A1 (ru)	2007-08-31
CA2448123A1 (en)	2002-11-28
US20060034852A1 (en)	2006-02-16
JP2009232856A (ja)	2009-10-15
KR101021124B1 (ko)	2011-03-14
NO20035173L (no)	2004-01-23

Publication	Publication Date	Title
RS20120253A1 (en)	2013-02-28	TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS
WO2002066516A3 (en)	2003-03-06	Antibodies that bind both bcma and taci
ATE473011T1 (de)	2010-07-15	Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen
IL184761A0 (en)	2007-12-03	Chromatographic media
WO2011038301A3 (en)	2011-07-07	Screening methods
MX2008000230A (es)	2008-04-07	Proteinas de enlace il-6.
WO2004101608A3 (en)	2004-12-29	Apo2l (trail) receptor binding peptides and uses thereof
AU2003270010A1 (en)	2004-03-19	Transferrin fusion protein libraries